Grace Therapeutics Inc (GRCE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.10-1.87%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GRCE
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||
| Revenues | — | — | — | — | — | 100.0 | 0.2 | — |
| Total Revenues | — | — | — | — | — | 100.0 | — | — |
| Cost of Revenues | — | — | — | — | — | 0.0 | 0.1 | — |
| Operating Expenses & Income | ||||||||
| R&D Expenses | 2.1 | 2.4 | 9.5 | 4.7 | 10.0 | 5.6 | 4.2 | 16.0 |
| Operating Income | (23.9) | (11.1) | (16.7) | (12.9) | (52.2) | (15.6) | (16.4) | (24.4) |
| Earnings from Continuing Operations | ||||||||
| Interest & Investment Income | 0.6 | 0.7 | 0.7 | 0.9 | 0.2 | 0.1 | 0.1 | 0.3 |
| Other Non-Operating Income / Expenses | 2.0 | 1.6 | 3.9 | (1.8) | 0.2 | 5.1 | (3.3) | (1.1) |
| Asset Writedown | — | — | — | — | — | — | 1.6 | 0.0 |
| EBT, Incl. Unusual Items | (21.9) | (9.5) | (12.8) | (14.7) | (52.0) | (10.5) | (19.7) | (25.5) |
| Income Tax Expense | — | (1.7) | (3.2) | (1.8) | (9.5) | (0.6) | 0.0 | 0.0 |
| Net Income | ||||||||
| Net Income | (20.2) | (7.8) | (9.6) | (12.9) | (42.4) | (9.8) | (19.7) | (25.5) |
| Per Share | ||||||||
| Basic EPS | (1.17) | (0.47) | (0.79) | (1.35) | (5.71) | (0.27) | — | — |
| Diluted EPS | (1.17) | (0.47) | (0.79) | (1.35) | (5.71) | (0.27) | — | — |
| Basic Weighted Avg Shares | 17.3 | 16.5 | 12.1 | 9.5 | 7.4 | 36.8 | — | — |
| Diluted Weighted Avg Shares | 17.3 | 16.5 | 12.1 | 9.5 | 7.4 | 36.8 | — | — |
| Supplemental | ||||||||
| EBIT | (23.9) | (11.1) | (16.7) | (12.9) | (52.2) | (15.6) | (16.4) | (24.4) |
| Effective Tax Rate | — | — | — | — | 18.4% | 6.2% | 0.0% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.